On July 14, 2025, Dare Bioscience, Inc. announced that its ongoing Phase 3 clinical trial for Ovaprene, a hormone-free contraceptive, had positive interim results, with no new safety concerns and favorable tolerability reported from about 115 participants. Approximately 9% of participants had pregnancies, while about 17% discontinued due to vaginal odor, and the study is continuing towards its goal of 250 participants.